Details, Fiction and Z-LEHD-fmk
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To judge many intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Principal demo goals had been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis clients,